A trial of NUC-1031 for advanced solid tumours

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

All cancer types




Phase 1

This trial is looking at a drug called NUC-1031 for solid tumours that have spread. A solid tumour Open a glossary item is any type of cancer other than leukaemia or lymphoma.

Doctors use a chemotherapy drug called gemcitabine to treat different types of cancer. But sometimes cancer stops responding to gemcitabine (it becomes resistant Open a glossary item to it).

NUC-1031 is very similar to gemcitabine, but it has been changed so that the drug is released directly into cancer cells. This may overcome resistance, but this is the first time NUC-1301has been tested in people.

The aims of the trial are to

  • Find the highest dose of NUC-1031 you can safely have and the best way to have it
  • Learn more about the side effects and what happens to the drug in your body
  • See if NUC-1031 helps people with advanced solid tumours

Who can enter

You may be able to join the trial if all of these apply. 

  • You have a cancer other than leukaemia or lymphoma (a solid tumour Open a glossary item)
  • Your cancer is not responding to other treatment or there is no standard treatment Open a glossary item available
  • You are well enough to be up and about for at least half the day (performance status 0, 1 or 2)
  • You are at least 18 years old
  • You have cancer that can be measured either on a scan or by measuring certain markers in your blood
  • You have satisfactory blood test results
  • You are willing to use reliable contraception during the trial and for 3 months afterwards if there is any chance you or your partner could become pregnant

You cannot enter this trial if you

  • Have cancer that has spread to your brain
  • Have had an allergic reaction to gemcitabine
  • Have had radiotherapy in the last 4 weeks unless it was to just 1 area of your body to control bone pain
  • Have had immunotherapy Open a glossary item or chemotherapy Open a glossary item in the last 4 weeks (in the last 6 weeks if you had a drug called mitomycin C or a drug called a nitrosourea Open a glossary item)
  • Have had hormone therapy or biological therapy in the last 2 weeks
  • Have not fully recovered from the side effects of other treatment unless they are very mild (apart from hair loss or nerve damage)
  • Have another illness that cannot be controlled with medication or an infection that needs treatment with antibiotics into a vein
  • Have any other medical condition or mental health problem that the trial team think could affect you taking part
  • Are known to be HIV, hepatitis B or hepatitis C positive
  • Are pregnant or breastfeeding

As well as the above, you can't enter the 2nd part of the trial if you have any other type of cancer apart from basal cell skin cancer, carcinoma in situ of the cervix or melanoma that is only in the outer layer of your skin (melanoma in situ).

Trial design

This phase 1 trial will recruit up to 95 people in total. Everybody taking part will have NUC-1031.

You have NUC-1031 as an injection into a vein in 3 out of every 4 weeks. It takes between 10 and 30 minutes each time. As the researchers are trying to find the best way to give the drug, some people taking part have injections once a week, some have them twice a week.

Each 4 week period is called a cycle of treatment. As long as you don’t have bad side effects, you have up to 6 cycles of treatment. If NUC-1031 seems to be helping you, the trial team may talk to you about having it for longer.

The trial is in 2 parts. In the first part, the researchers want to find the highest dose of NUC-1031 you can safely have. The first few patients will have a low dose. If they don’t have any serious side effects, the next patients will have a higher dose. And so on, until they find the best dose to give. This is called a dose escalation study.

In the second part of the trial, researchers want to learn more about the safety of NUC-1031 and the effect it has on certain cancers. Everybody will have the highest safe dose that was found in part 1. And everybody will have the injections in the same way – either once a week or twice a week, depending on the results of part 1.

Hospital visits

You see the trial team and have some tests before you start treatment. The tests include

  • Physical examination
  • Blood tests
  • Heart trace (ECG Open a glossary item)
  • CT scan

You may have an extra scan called a PET-CT scan.

The trial team will ask for a sample of the tissue that was removed when you had surgery to remove your cancer or a biopsy Open a glossary item. If you join the 2nd part of the trial and there isn’t a tissue sample available, the trial team will ask you to have a biopsy before you start treatment. But you don't have to agree to have this biopsy if you don't want to. You can still take part in the trial.

You go to hospital once or twice a week during treatment, depending on how often you have the injections. You have regular blood tests and a CT scan every 2 months. When you finish treatment, you see the trial team again about 4 weeks later.

Side effects

As this is the first time NUC-1031 has been tested in people, there may be side effects we don’t know about yet. But as it is very similar to gemcitabine, the researchers expect the side effects to be similar. These include

We have more information about gemcitabine.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Sarah Blagden

Supported by

Experimental Cancer Medicine Centre (ECMC)
Imperial College London
NuCana BioMed

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 10708

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page